News Releases & Research Results Regulatory approval for ALK inhibitor alectinib for recurrent/refractory ALK-positive anaplastic large cell lymphoma

The results of collaborative research and development led by National Hospital Organization Nagoya Medical Center, St. Marianna University School of Medicine, and National Hospital Organization Kyushu Cancer Center.

• An investigator-initiated clinical trial evaluated the efficacy and safety of ALK inhibitor alectinib for recurrent/refractory ALK-positive anaplastic large cell lymphoma, designated as a rare disease.
• The trial showed a high efficacy of alectinib, to which 80 percent of the patients responded.
• Alectinib has become the world’s first ALK inhibitor approved for ALK-positive anaplastic large cell lymphoma.

This R&D project was conducted with the support of Practical Research for Innovative Cancer Control by AMED.